Background/Aim: This study aimed to demonstrate the clinical outcomes of primary vitreoretinal lymphoma (PVRL). Patients and Methods: Seventeen patients with PVRL who had been treated at Hokkaido University Hospital were enrolled in this study. They were diagnosed based on their cytology, interleukin-10/-6 ratio, and immunoglobulin heavy chain (IgH) gene rearrangement. Results: Diagnostic tests detected cytological malignancy among 14 cases (82.3%), high interleukin-10/-6 ratios among 16 cases (94.1%), and IgH monoclonality in 13 cases (76.5%). Systemic corticosteroids were given to seven (41.2%) patients before their diagnosis of PVRL. Treatments after diagnosis comprised intravitreal methotrexate injection, local radiation, and intravenous chemotherapy for 11, seven, and five cases, respectively. Central nervous system and systemic involvements were observed in nine and one case, respectively, and these complications occurred at 3 to 43 months (mean=16 months) after initial ocular presentation. Conclusion: Many of our patients did not receive any systemic intervention, and almost half of patients with PVRL developed central nervous system involvement during their follow-up period. Copyright 2021, International Institute of Anticancer Research.
Background/Aim: This study aimed to demonstrate the clinical outcomes of primary vitreoretinal lymphoma (PVRL). Patients and Methods: Seventeen patients with PVRL who had been treated at Hokkaido University Hospital were enrolled in this study. They were diagnosed based on their cytology, interleukin-10/-6 ratio, and immunoglobulin heavy chain (IgH) gene rearrangement. Results: Diagnostic tests detected cytological malignancy among 14 cases (82.3%), high interleukin-10/-6 ratios among 16 cases (94.1%), and IgH monoclonality in 13 cases (76.5%). Systemic corticosteroids were given to seven (41.2%) patients before their diagnosis of PVRL. Treatments after diagnosis comprised intravitreal methotrexate injection, local radiation, and intravenous chemotherapy for 11, seven, and five cases, respectively. Central nervous system and systemic involvements were observed in nine and one case, respectively, and these complications occurred at 3 to 43 months (mean=16 months) after initial ocular presentation. Conclusion: Many of our patients did not receive any systemic intervention, and almost half of patients with PVRL developed central nervous system involvement during their follow-up period. Copyright 2021, International Institute of Anticancer Research.
Entities:
Keywords:
Vitreoretinal lymphoma; central nervous system involvement; diagnosis; treatment
Authors: Maria Vittoria Cicinelli; Alessandro Marchese; Elisabetta Miserocchi; Chiara Giuffré; Luigi Berchicci; Giuseppe Querques; Francesco Bandello; Giulio Maria Modorati Journal: Ocul Immunol Inflamm Date: 2019-08-08 Impact factor: 3.070
Authors: Patrick G Morris; Denise D Correa; Joachim Yahalom; Jeffrey J Raizer; David Schiff; Barbara Grant; Sean Grimm; Rose K Lai; Anne S Reiner; Kathy Panageas; Sasan Karimi; Richard Curry; Gaurav Shah; Lauren E Abrey; Lisa M DeAngelis; Antonio Omuro Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: Justine R Smith; Jacob Pe'er; Rubens N Belfort; Fatima Cardoso; Richard D Carvajal; Carlos Carvalho; Sarah E Coupland; Laurence Desjardins; Jasmine H Francis; Brenda L Gallie; Dan S Gombos; Hans E Grossniklaus; Steffen Heegaard; Martine J Jager; Swathi Kaliki; Bruce R Ksander; Markus Maeurer; Eduardo Moreno; Jose S Pulido; Bettina Ryll; Arun D Singh; Junyang Zhao; António Parreira; David J Wilson; Joan M O'Brien Journal: Transl Vis Sci Technol Date: 2018-01-09 Impact factor: 3.283